Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger B Cohen

Showing results (81-90 of 208) with videos related to

Pageof 21
Sort By:
The British Journal of Radiology|November 13, 2015
Nodal metastasis and elective nodal level treatment in sinonasal small-cell and sinonasal undifferentiated carcinoma: a surveillance, epidemiology and end results analysisPeter H Ahn, Nandita Mitra, Michelle Alonso-Basanta, et al.
Clinical Colorectal Cancer|February 11, 2009
An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumorsJoe J Stephenson, Charles Gregory, Howard Burris, et al.
Investigational New Drugs|January 25, 2014
A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumorsMargaret von Mehren, Carolyn D Britten, Peter Pieslor, et al.
The Journal of Rheumatology|April 17, 2013
Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial programMichael E Weinblatt, Larry W Moreland, Rene Westhovens, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapyCharu Aggarwal, Xingmei Wang, Anjana Ranganathan, et al.
Investigational New Drugs|November 20, 2012
A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumorsJohn Marshall, Jimmy Hwang, Ferry A L M Eskens, et al.
The Journal of Liquid Biopsy|April 13, 2026
The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testingBenjamin A Bleiberg, Dylan G Scholes, Lauren Reed-Guy, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 6, 2014
Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumorsPasi A Jänne, Roger B Cohen, A Douglas Laird, et al.
The Journal of Liquid Biopsy|June 29, 2026
Erratum to "The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing" [J. Liq. Biopsy 12 (2026) 100461]Benjamin A Bleiberg, Dylan G Scholes, Lauren Reed-Guy, et al.
Diabetes Care|July 24, 2019
Lung Cancer-Related Mortality With Inhaled Insulin or a Comparator: Follow-Up Study of patients previously enrolled in Exubera Controlled Clinical Trials (FUSE) Final ResultsNicolle M Gatto, Daniel O Koralek, Michael B Bracken, et al.
Pageof 21

Showing results (81-90 of 208) with videos related to

Sort By:
Pageof 21
The British Journal of Radiology|November 13, 2015
Nodal metastasis and elective nodal level treatment in sinonasal small-cell and sinonasal undifferentiated carcinoma: a surveillance, epidemiology and end results analysisPeter H Ahn, Nandita Mitra, Michelle Alonso-Basanta, et al.
Clinical Colorectal Cancer|February 11, 2009
An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumorsJoe J Stephenson, Charles Gregory, Howard Burris, et al.
Investigational New Drugs|January 25, 2014
A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumorsMargaret von Mehren, Carolyn D Britten, Peter Pieslor, et al.
The Journal of Rheumatology|April 17, 2013
Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial programMichael E Weinblatt, Larry W Moreland, Rene Westhovens, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapyCharu Aggarwal, Xingmei Wang, Anjana Ranganathan, et al.
Investigational New Drugs|November 20, 2012
A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumorsJohn Marshall, Jimmy Hwang, Ferry A L M Eskens, et al.
The Journal of Liquid Biopsy|April 13, 2026
The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testingBenjamin A Bleiberg, Dylan G Scholes, Lauren Reed-Guy, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 6, 2014
Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumorsPasi A Jänne, Roger B Cohen, A Douglas Laird, et al.
The Journal of Liquid Biopsy|June 29, 2026
Erratum to "The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing" [J. Liq. Biopsy 12 (2026) 100461]Benjamin A Bleiberg, Dylan G Scholes, Lauren Reed-Guy, et al.
Diabetes Care|July 24, 2019
Lung Cancer-Related Mortality With Inhaled Insulin or a Comparator: Follow-Up Study of patients previously enrolled in Exubera Controlled Clinical Trials (FUSE) Final ResultsNicolle M Gatto, Daniel O Koralek, Michael B Bracken, et al.
Pageof 21